News|Articles|February 4, 2026

6 Hematology Headlines You Missed in January 2026

January 2026 Hematology Month in Review highlights new ASH and KDIGO guidelines, FDA approvals, and pipeline progress in rare blood disorders.

January 2026 brought a wave of clinically meaningful updates across hematology, spanning new clinical practice guidelines, regulatory approvals, and late-stage pipeline momentum in both malignant and nonmalignant disease. Organizations including the American Society of Hematology (ASH) and Kidney Disease: Improving Global Outcomes (KDIGO) released updated guidance aimed at improving diagnostic accuracy and supportive care, while the US Food and Drug Administration (FDA) expanded treatment options for rare bleeding and thrombotic disorders.

Related to this article

September 21st, 2026

FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B

FDA expands marstacimab approval to children and patients with inhibitors, backed by new BASIS trial data.

September 20th, 2026

The HCPFive: Top News for Healthcare Providers from the Week of 09/13

Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.

September 25th, 2026

FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata

Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.

Image Credit: US Food and Drug Administration

September 25th, 2026

Zilurgisertib Receives FDA Approval for FOP in Patients 12 and Older

The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.

September 25th, 2026

FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome

Approval covers patients aged ≥2 years with frequently relapsing or steroid dependent disease in complete remission.

September 25th, 2026

What The FDA Psychedelic Hearing Means for Psychiatrists

As the FDA weighs its first psychedelic approval, Sarah Norman, MPP, says training, credentialing, and reimbursement are lagging while patients are already asking.

September 25th, 2026

The Case for Routine Kidney Screening, With Pranav Garimella, MBBS, MPH

Pranav Garimella discusses what a potential USPSTF kidney screening recommendation could mean for high-risk adults and primary care.

September 24th, 2026

The Medical Sisterhood: Is Becoming a Doctor Still Worth It?

Andrea Murina, MD, weighs whether she would recommend medicine to her own children amid AI, physician burnout, and evolving residency training standards.